CN101291927A - 可用作蛋白激酶抑制剂的苯并咪唑 - Google Patents

可用作蛋白激酶抑制剂的苯并咪唑 Download PDF

Info

Publication number
CN101291927A
CN101291927A CNA2006800343024A CN200680034302A CN101291927A CN 101291927 A CN101291927 A CN 101291927A CN A2006800343024 A CNA2006800343024 A CN A2006800343024A CN 200680034302 A CN200680034302 A CN 200680034302A CN 101291927 A CN101291927 A CN 101291927A
Authority
CN
China
Prior art keywords
compound
independently
group
formula
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800343024A
Other languages
English (en)
Chinese (zh)
Inventor
H·宾奇
M·莫蒂默尔
D·罗宾森
D·斯塔默斯
S·艾弗里特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN101291927A publication Critical patent/CN101291927A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CNA2006800343024A 2005-07-26 2006-07-21 可用作蛋白激酶抑制剂的苯并咪唑 Pending CN101291927A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70239905P 2005-07-26 2005-07-26
US60/702,399 2005-07-26

Publications (1)

Publication Number Publication Date
CN101291927A true CN101291927A (zh) 2008-10-22

Family

ID=37680602

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800343024A Pending CN101291927A (zh) 2005-07-26 2006-07-21 可用作蛋白激酶抑制剂的苯并咪唑

Country Status (17)

Country Link
US (1) US8076343B2 (enExample)
EP (2) EP1937667B1 (enExample)
JP (2) JP5255438B2 (enExample)
KR (1) KR20080034483A (enExample)
CN (1) CN101291927A (enExample)
AT (1) ATE484501T1 (enExample)
AU (1) AU2006276088A1 (enExample)
CA (1) CA2616159A1 (enExample)
DE (1) DE602006017574D1 (enExample)
ES (1) ES2351357T3 (enExample)
IL (1) IL188942A0 (enExample)
NO (1) NO20080967L (enExample)
NZ (1) NZ566021A (enExample)
RU (1) RU2415853C2 (enExample)
TW (1) TW200745088A (enExample)
WO (1) WO2007015923A2 (enExample)
ZA (1) ZA200800992B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112552287A (zh) * 2020-12-16 2021-03-26 北京华氏开元医药科技有限公司 一种吲哚类衍生物药物制剂及其制备方法
WO2023116888A1 (zh) * 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2920996A1 (en) 2007-10-19 2009-04-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
AU2009248923B2 (en) 2008-05-21 2015-01-29 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9336046B2 (en) 2012-06-15 2016-05-10 International Business Machines Corporation Transaction abort processing
US9512136B2 (en) * 2012-11-26 2016-12-06 Universal Display Corporation Organic electroluminescent materials and devices
WO2014147203A1 (en) * 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014170421A1 (en) * 2013-04-19 2014-10-23 F. Hoffmann-La Roche Ag Serine/threonine kinase inhibitors
ITUA20164278A1 (it) * 2016-06-10 2017-12-10 International Soc For Drug Development S R L COMPOSTI 2-OXO-1,2-DIIDROPIRIDIN-3-CARBOSSAMMIDE E LORO USO COME INIBITORI DUALI DI PDK1/AurA
US10793551B2 (en) 2017-10-19 2020-10-06 Effector Therapeutics Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143157A0 (en) 1998-11-17 2002-04-21 Kumiai Chemical Industry Co Pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives and agricultural/horticultural bactericides
JP4535350B2 (ja) * 1998-11-17 2010-09-01 クミアイ化学工業株式会社 ピリミジニルベンズイミダゾール誘導体及び農園芸用殺菌剤
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
DE60217322T2 (de) * 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
WO2003099811A1 (en) * 2002-05-23 2003-12-04 Cytopia Pty Ltd Kinase inhibitors
CL2003002353A1 (es) * 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB2432834A (en) * 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112552287A (zh) * 2020-12-16 2021-03-26 北京华氏开元医药科技有限公司 一种吲哚类衍生物药物制剂及其制备方法
CN112552287B (zh) * 2020-12-16 2021-11-30 北京华氏精恒医药科技有限公司 一种吲哚类衍生物药物制剂及其制备方法
WO2023116888A1 (zh) * 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用

Also Published As

Publication number Publication date
CA2616159A1 (en) 2007-02-08
IL188942A0 (en) 2008-04-13
EP1937667B1 (en) 2010-10-13
JP2009502921A (ja) 2009-01-29
ATE484501T1 (de) 2010-10-15
RU2415853C2 (ru) 2011-04-10
KR20080034483A (ko) 2008-04-21
ES2351357T3 (es) 2011-02-03
WO2007015923A2 (en) 2007-02-08
EP2336122A1 (en) 2011-06-22
WO2007015923A8 (en) 2008-04-03
ZA200800992B (en) 2009-09-30
AU2006276088A1 (en) 2007-02-08
EP1937667A2 (en) 2008-07-02
JP5255438B2 (ja) 2013-08-07
NZ566021A (en) 2011-03-31
RU2008106949A (ru) 2009-09-10
WO2007015923A3 (en) 2007-04-19
EP2336122B1 (en) 2014-05-14
US8076343B2 (en) 2011-12-13
JP2013082757A (ja) 2013-05-09
TW200745088A (en) 2007-12-16
NO20080967L (no) 2008-04-22
DE602006017574D1 (de) 2010-11-25
US20070099920A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
EP1562938B1 (en) Heteroaryl-pyrimidine derivatives as jak inhibitors
TWI501768B (zh) 嗒酮衍生物
US7312227B2 (en) Compositions useful as inhibitors of JAK and other protein kinases
CN103124730B (zh) 杂环炔苯类化合物及其药用组合物和应用
JP2013082757A (ja) プロテインキナーゼ阻害薬として有用なベンズイミダゾール
CA2946130A1 (en) Quinoxaline compounds and uses thereof
AU2004215428A1 (en) Aminoheteroaryl compounds as protein kinase inhibitors
CN101687852A (zh) 可用作激酶抑制剂的噻唑类和吡唑类化合物
CN101679378A (zh) 用作激酶抑制剂的噻唑和吡唑
CA2942687A1 (en) 5-substituted indazole-3-carboxamides and preparation and use thereof
BRPI0720635A2 (pt) Compostos orgânicos e seus usos
CN101848909A (zh) 可用作蛋白激酶抑制剂的吡咯并[3,2-c]吡啶
CN101801959A (zh) 可用作激酶抑制剂的氨基嘧啶类化合物
CN101679387A (zh) 可用作激酶抑制剂的氨基嘧啶类化合物
CN101679386A (zh) 可用作激酶抑制剂的氨基嘧啶类化合物
CA2974078A1 (en) Quinazoline and quinoline compounds and uses thereof
ES2433469T3 (es) Moduladores de la aurora cinasa y métodos de uso
CA3147443A1 (en) Compounds and method for treating cytokine release syndrome
HK1122558A (en) Benzimidazoles useful as inhibitors of protein kinases
CN101273032A (zh) 吡嗪激酶抑制剂
MX2008001172A (en) Benzimidazoles useful as inhibitors of protein kinases
HK1138587A (en) Thiazoles and pyrazoles useful as kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1122558

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20081022

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1122558

Country of ref document: HK